Aradigm Corporation to Host First Quarter 2001 Conference Call

Apr 17, 2001, 01:00 ET from Aradigm Corporation

    HAYWARD, Calif., April 17 /PRNewswire/ -- Aradigm Corporation
 (Nasdaq:   ARDM) today announced that the company will host a conference call
 and question and answer session on Thursday, April 26, 2001, to discuss the
 financial results for the first quarter of 2001.
 
      Date:          Thursday, April 26, 2001
      Time:          1:30 pm Eastern, 10:30 am Pacific
      Internet:      www.aradigm.com
      Telephone:     (800) 589-4298
                     International callers, dial (719) 457-2620
                     Access code: 503555
 
     A replay of the conference call will be available for one week following
 the call, which can be accessed on www.aradigm.com or by dialing (888) 203-
 1112.  International callers should dial (719) 457-0820.  The replay access
 code is 503555.
 
     Aradigm is working to improve the quality of life of patients by
 developing aerosol-based drug delivery alternatives to injectable
 therapeutics. The Company's advanced pulmonary delivery technologies provide
 leading pharmaceutical and biotechnology partners with effective drug delivery
 solutions. Current development programs focus on diabetes, pain management,
 and the pulmonary delivery of existing and emerging biotech therapeutics.
 
     Based in Hayward, California, Aradigm is currently developing products for
 diabetes management with Novo Nordisk A/S, the world leader in insulin and
 diabetes care, and breakthrough and acute pain management for GlaxoSmithKline,
 a world leader in oncology therapy and supportive care. In addition, Aradigm
 has four additional partner-funded programs and a gene therapy effort funded
 through the National Institutes of Health. More information about Aradigm can
 be found at www.aradigm.com. Investors may also request company information
 via email by directing inquiries to investor@aradigm.com.
 
     Please note:
     Except for the historical information contained herein, this news release
 contains forward-looking statements that involve risk and uncertainties,
 including the timely availability and acceptance of new products, the impact
 of competitive products and pricing, and the management of growth, as well as
 the other risks detailed from time to time in Aradigm Corporation's Securities
 and Exchange Commission (SEC) Registration Statements, including the company's
 Annual Report on Form 10-K as amended.
 
      AT ARADIGM CORPORATION:
      Norman Halleen
      Chief Financial Officer
      (510) 265-9000
 
      MEDIA AND INVESTORS:
      Kari Lampka
      Feinstein Kean Healthcare
      (617) 577-8110
 
 

SOURCE Aradigm Corporation
    HAYWARD, Calif., April 17 /PRNewswire/ -- Aradigm Corporation
 (Nasdaq:   ARDM) today announced that the company will host a conference call
 and question and answer session on Thursday, April 26, 2001, to discuss the
 financial results for the first quarter of 2001.
 
      Date:          Thursday, April 26, 2001
      Time:          1:30 pm Eastern, 10:30 am Pacific
      Internet:      www.aradigm.com
      Telephone:     (800) 589-4298
                     International callers, dial (719) 457-2620
                     Access code: 503555
 
     A replay of the conference call will be available for one week following
 the call, which can be accessed on www.aradigm.com or by dialing (888) 203-
 1112.  International callers should dial (719) 457-0820.  The replay access
 code is 503555.
 
     Aradigm is working to improve the quality of life of patients by
 developing aerosol-based drug delivery alternatives to injectable
 therapeutics. The Company's advanced pulmonary delivery technologies provide
 leading pharmaceutical and biotechnology partners with effective drug delivery
 solutions. Current development programs focus on diabetes, pain management,
 and the pulmonary delivery of existing and emerging biotech therapeutics.
 
     Based in Hayward, California, Aradigm is currently developing products for
 diabetes management with Novo Nordisk A/S, the world leader in insulin and
 diabetes care, and breakthrough and acute pain management for GlaxoSmithKline,
 a world leader in oncology therapy and supportive care. In addition, Aradigm
 has four additional partner-funded programs and a gene therapy effort funded
 through the National Institutes of Health. More information about Aradigm can
 be found at www.aradigm.com. Investors may also request company information
 via email by directing inquiries to investor@aradigm.com.
 
     Please note:
     Except for the historical information contained herein, this news release
 contains forward-looking statements that involve risk and uncertainties,
 including the timely availability and acceptance of new products, the impact
 of competitive products and pricing, and the management of growth, as well as
 the other risks detailed from time to time in Aradigm Corporation's Securities
 and Exchange Commission (SEC) Registration Statements, including the company's
 Annual Report on Form 10-K as amended.
 
      AT ARADIGM CORPORATION:
      Norman Halleen
      Chief Financial Officer
      (510) 265-9000
 
      MEDIA AND INVESTORS:
      Kari Lampka
      Feinstein Kean Healthcare
      (617) 577-8110
 
 SOURCE  Aradigm Corporation